Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Novartis CEO joins Anthropic Board of Directors, with independent trustees appointing the first majority of seats
ME News report, April 14 (UTC+8). According to monitoring by 1M AI News, Anthropic announced that Vas Narasimhan, CEO of Novartis, a global pharmaceutical giant, has joined its board of directors, appointed by the company’s Long-Term Benefit Trust. After this appointment, the trust-appointed directors now hold a majority of seats on the seven-member board for the first time.
Anthropic’s Long-Term Benefit Trust is an independent organization. Its members have no financial interests in Anthropic, and their duty is to ensure that corporate governance remains balanced between commercial success and the company’s public welfare mission. Currently, the board has seven members: Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, Chris Liddell, and Narasimhan.
Narasimhan is a medical scientist. During his tenure as Novartis CEO, he led the R&D and approvals for more than 35 new drugs. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis projects in India, Africa, and South America, and he is now a member of the U.S. National Academy of Medicine. Daniela Amodei, co-founder and president of Anthropic, said that Narasimhan’s experience in one of the most heavily regulated industries in the world will help bring powerful new technologies to the market safely and at scale—something Anthropic is doing every day.
(Source: BlockBeats)